Trospium Cl — Competitive Intelligence Brief

Trospium Cl (Trospium Cl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Urology.

marketed Anticholinergic agent Muscarinic acetylcholine receptors (M3 subtype) Urology Small molecule

Target snapshot

Trospium Cl (Trospium Cl) — Toronto Rehabilitation Institute. Trospium chloride is an anticholinergic agent that blocks muscarinic receptors in the bladder smooth muscle, reducing involuntary contractions and urinary urgency.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trospium Cl TARGET	Trospium Cl	Toronto Rehabilitation Institute	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3 subtype)
scopolamine patch	scopolamine patch	Rutgers, The State University of New Jersey	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1, M3, M5)
Atropine Sulfate 0.04% Eye Drop	Atropine Sulfate 0.04% Eye Drop	Shanghai Eye Disease Prevention and Treatment Center	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3, M5)
Neostigmine+Glycopyrronium	Neostigmine+Glycopyrronium	Pusan National University Yangsan Hospital	marketed	Acetylcholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase; Muscarinic acetylcholine receptors
Neostigmine + Atropine	Neostigmine + Atropine	China Medical University Hospital	marketed	Cholinesterase inhibitor + Anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (atropine)
Postop orphenadrine IV	Postop orphenadrine IV	AdventHealth	marketed	Anticholinergic agent / Muscle relaxant	Muscarinic acetylcholine receptors
Intravenous scopolamine hydrobromide	Intravenous scopolamine hydrobromide	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class